Core Viewpoint - The announcement highlights that the company's wholly-owned subsidiary, Gaoshi Tailiang Medical Technology Co., Ltd., has received medical device registration approval from the Guangdong Provincial Drug Administration for its "artificial lens implantation system" [1] Group 1: Product Details - The artificial lens implantation system is designed for use in micro-incision cataract surgery, optimizing the surgical incision to less than 1.8mm, which minimizes corneal trauma and accelerates postoperative recovery [1] - The product is an original design by Gaoshi Tailiang and has been granted an invention patent [1] Group 2: Regulatory Approval - The approval from the Guangdong Provincial Drug Administration marks a significant milestone for the company, as it allows the commercialization of the new artificial lens implantation system [1] - This system is compared to the one approved in 2024, indicating advancements in surgical techniques and technology [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 人工晶狀體植入系統獲得中國醫療器械註冊證 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，近日本公司全資附屬公司高視 泰靚醫療科技有限公司（「高視泰靚」）之「人工晶狀體植入系統」已獲得由廣東 省藥品監督管理局批准的醫療器械註冊證。 根據《中國成人白內障摘除手術指南(2023)》內容顯示，白內障是全球首位致盲 性疾病。隨著人口老齡化加劇，白內障發病率逐年增高，截至2020年，中國成 人（18歲及以上）白內障的發病率達到22.78%。患者數量已高達1.3億，預計到 2050年，中國成人白內障人群將超過 ...

Core Viewpoint - The stock price of Gaoshi Medical (02407) experienced a significant decline of 15.99% on April 7 due to external factors, but has since begun a slow recovery, closing at HKD 6.05 on May 7, surpassing the closing price on April 6. However, the overall decline in April was 3.53%, underperforming the Hang Seng Healthcare sector, which saw a gain of 1.10% during the same period [1]. Group 1: Stock Performance and Market Context - The Hang Seng Index dropped 13.2% on April 7, marking the largest single-day decline since the Asian financial crisis, while the Hang Seng Healthcare Index fell by 19.01% [1]. - In the following 10 trading days, the Hang Seng Healthcare Index rebounded to 2978.74 points, outperforming Gaoshi Medical, attributed to active southbound capital providing liquidity [1][2]. - In April, the Hong Kong Stock Connect channel recorded a turnover of nearly HKD 2.3 trillion, accounting for 43.8% of the market's total turnover, with a net buy of over HKD 166.6 billion, setting a new monthly record [2]. Group 2: Impact of Stock Connect Removal - Gaoshi Medical's stock price recovery lagged behind the sector due to its removal from the Stock Connect, which took effect on March 10. Stocks added to the Stock Connect saw an average price increase of 0.72%, while those removed, including Gaoshi Medical, experienced an average decline of 14.24% [3]. - The average market capitalization of Gaoshi Medical during the review period was HKD 2.464 billion, falling short of the HKD 4 billion threshold by HKD 1.536 billion, leading to its exclusion from the Stock Connect [3]. Group 3: Financial Performance and Challenges - For the fiscal year 2024, Gaoshi Medical reported revenue of RMB 1.428 billion, a year-on-year increase of 1.6%, but a gross profit decline of 4.1% to RMB 663 million, with net profit attributable to shareholders dropping by 46.75% to RMB 92.394 million [8]. - The decline in profitability was attributed to factors such as exchange rate fluctuations and the implementation of national procurement policies for artificial crystals, resulting in a gross margin reduction [8]. - The company faced significant goodwill impairment due to poor performance of acquired companies, with cumulative impairments reaching RMB 23.257 million by the end of 2024 [9]. Group 4: Research and Development Investment - To enhance competitiveness, Gaoshi Medical increased its R&D expenditure by 48.29% to RMB 78.418 million in 2024, with R&D spending as a percentage of self-owned product revenue rising to 5.5% [10][11]. - Despite efforts to shift from distribution products to self-owned products, the revenue from distribution products increased to 68.55% in 2024, indicating challenges in optimizing the revenue structure [12].

(Stock Code: 2407) （股 份 代 號：2407） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders: Gaush Meditech Ltd (the "Company") — Notice of publication of 2024 Annual Report, Circular, Proxy Form and Notice of Annual General Meeting (the "Current Corporate Communication") Gaush Meditech Ltd 高視醫療科技有限公司 (Incorporated in the Cayman Islands with limited liability) （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） — 刊發2024年年度報告、通函、委任表格及股東週年大會通告（「本次公司通訊」） 本公司的本次公司通訊之中文、英文版本已分別上載於本公司網站( www.gaush.com )及香港聯合交易所有限公司（「聯交所」）之網 站( www.h ...

Gaush Meditech Ltd 高視醫療科技有限公司 (Incorporated in the Cayman Islands with limited liability) （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） (Stock Code: 2407) （股 份 代 號：2407） NOTIFICATION LETTER 通知信函 Notes: 各位非登記持有人 （附註1） ： 高視醫療科技有限公司（「本公司」） — 刊發2024年年度報告、通函及股東週年大會通告（「本次公司通訊」） Dear Non-registered Holder(s) (Note 1) : Gaush Meditech Ltd (the "Company") — Notification of publication of 2024 Annual Report, Circular and Notice of Annual General Meeting (the "Current Corporate Communication") The English and Chinese versions o ...

Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 股東週年大會通告 茲通告高視醫療科技有限公司（「本公司」）謹訂於2025年5月29日（星期四）下午三時 正假座中國北京市東城區東直門南大街11號中匯廣場A座1901室舉行股東週年大會（「股 東週年大會」），以處理下列事項： 普通決議案 – 1 – 1. 省覽及採納本公司截至2024年12月31日止年度的經審核綜合財務報表、董事會報 告及核數師報告。 2. (a) 重選以下退任的本公司董事（「董事」）： (i) 重選高鐵塔先生為執行董事； (ii) 重選劉新偉先生為執行董事； (iii) 重選David Guowei Wang博士為非執行董事；及 (b) 授權董事會（「董事會」）釐定董事的薪酬。 3. 續聘安永會計師事務所為本公司核數師，並授權董事會釐定其酬金。 – 2 – 4. 考慮及酌情通過（不論有否修訂）下列決議案為普通決議案： (A) 「動議： (i) 在下文第(iii)段的規限下，一般及無條件批准董事於有關期間（定義見 下文）內行使本公司一切 ...

此乃要件 請即處理 閣下如對本通函或應採取的行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證 券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有高視醫療科技有限公司股份，應立即將本通函及隨附的 代表委任表格送交買主或承讓人，或經手買賣或轉讓的銀行、股票經紀或其他代理商， 以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 建議 發行股份及購回股份的一般授權、 重選退任董事、 宣派末期股息 及 股東週年大會通告 高視醫療科技有限公司謹訂於2025年5月29日（星期四）下午三時正假座中國北京市東城 區東直門南大街11號中匯廣場A座1901室舉行股東週年大會，大會通告載於本通函第21 至26頁。隨函亦附奉股東週年大會適用的代表委任表格。該代表委任 ...

Financial Performance - The company's revenue for the year ended December 31, 2024, was RMB 1,428.4 million, an increase of 1.6% compared to RMB 1,406.2 million for the year ended December 31, 2023[11]. - The net profit for the year ended December 31, 2024, was RMB 88.5 million, a decrease of 48.8% from RMB 172.9 million in 2023[11]. - Basic earnings per share for the year ended December 31, 2024, were RMB 0.63, down from RMB 1.17 in 2023[11]. - The board proposed a final dividend of HKD 0.3 per share for the year ended December 31, 2024, compared to HKD 1.1 per share in 2023[11]. - The company's gross profit for the same period was RMB 663.4 million, which is a decrease of 4.1% year-over-year[21]. - Sales cost rose by 7.1% from RMB 714.6 million to RMB 765.0 million, slightly outpacing revenue growth due to rising material costs and procurement prices[41]. - Gross profit decreased by 4.1% from RMB 691.6 million to RMB 663.4 million, with gross margin dropping from 49.2% to 46.4%[42]. - Other income and gains fell by 41.3% from RMB 45.0 million to RMB 26.4 million, primarily due to foreign exchange losses[43]. - The company recorded a net profit of RMB 88.5 million for the year ending December 31, 2024, down from RMB 172.9 million for the previous year[51]. Product Development and Innovation - The company has successfully launched three domestically developed single-focus intraocular lenses and is currently developing high-end domestic intraocular lenses[13]. - A new generation of dry eye examination products has been registered and officially launched for sale[13]. - The company is advancing AI diagnostic screening applications and smart manufacturing technologies in its product development[13]. - The company achieved MDR CE certification for its hydrophilic acrylic intraocular lens product line, marking a significant milestone[13]. - The company has established a "Global 4+2" R&D layout, with 265 R&D personnel, accounting for approximately 30% of total staff[28]. - R&D expenditure for the reporting period was RMB 78.4 million, representing 20.9% of proprietary product revenue, indicating a strong focus on innovation[28]. - The company aims to enhance its R&D capabilities, which accounted for 38.2% of the net proceeds allocation[119]. Market Expansion and Partnerships - The company has established exclusive distribution agreements with 16 out of 18 overseas brand partners, enhancing its product portfolio and market position[14]. - The company’s overseas business has expanded, participating in large-scale exhibitions with over 5,000 attendees and achieving MDR CE certification for its hydrophilic acrylic intraocular lens product line[33]. - The company’s products are now sold in 52 countries and regions, with its Roland products available in 33 countries[34]. - The company has established exclusive distribution agreements with 16 overseas brand partners, including a new partnership with South Korea's Sometech Inc. for 3D 4K digital ophthalmic surgical microscopes[31]. - The company aims to enhance its product offerings and expand its market presence in Asia and Europe, while optimizing management processes for improved efficiency[19]. Financial Position and Cash Management - As of December 31, 2024, the group's cash and cash equivalents amounted to RMB 421.4 million, a decrease of 31.9% from RMB 618.7 million as of December 31, 2023, primarily due to dividend payments of RMB 148.5 million and loan repayments of approximately RMB 109.7 million during the reporting period[64]. - The group's debt-to-asset ratio as of December 31, 2024, was 34.8%, down from 39.1% as of December 31, 2023[68]. - The group continues to maintain a strong cash flow and financial resources to support its operational and expansion plans[64]. - The group has implemented internal control measures to enhance cash management and reduce financial risks[64]. - The fair value financial assets decreased from RMB 175.6 million as of December 31, 2023, to RMB 97.7 million as of December 31, 2024, reflecting the company's focus on enhancing cash management efficiency and seeking high-return investment opportunities[52]. Employee and Management Structure - The total employee cost for the group for the year ended December 31, 2024, was RMB 375.2 million, compared to RMB 352.5 million for the year ended December 31, 2023, reflecting an increase of approximately 6.1%[140]. - The group had a total of 884 employees as of December 31, 2024, up from 869 employees as of December 31, 2023[140]. - The company emphasizes talent development and cultural construction as part of its strategic initiatives[80]. - The leadership team is well-educated, with degrees from prestigious institutions such as the University of Wisconsin-Madison and Peking University[81][88]. - The company has a strong focus on compliance and internal audit functions, overseen by Zhao Xinli as Chief Compliance Officer[79]. Governance and Compliance - The board consists of five executive directors, one non-executive director, and three independent non-executive directors, maintaining compliance with listing rules[194]. - The independent non-executive directors play a crucial role in providing unbiased opinions on the company's strategy and performance[197]. - The company has adopted a corporate governance code to ensure compliance and protect shareholder interests[187]. - The board has established three committees: audit, remuneration, and nomination, to oversee specific aspects of governance[193]. - The board confirmed the independence of all independent non-executive directors throughout the reporting period[133]. Shareholder Information - Major shareholders include GT HoldCo with 63,263,528 shares, representing 42.78% of the total issued share capital[161]. - OrbiMed Advisors III Limited and its affiliates collectively hold 18,039,426 shares, accounting for 12.20% of the total issued share capital[161]. - The company has maintained a minimum of 25% public shareholding throughout the reporting period[177]. - The company has sufficient financial resources to implement share repurchases while maintaining a sound financial position[165]. - The company repurchased a total of 82,500 shares during the reporting period, at a total cost of HKD 976,492, representing 0.056% of the total issued shares[165].

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 近日， 高视医疗 （02407.HK）全资附属公司北京高视远望科技有限责任公司所代理的德国 海德堡 （ Heidelberg）公司出品的 ANTERION 眼科检测仪（三合一眼前节多模影像诊断平台） 获得中国药监局 医疗器械注册证 ，该仪器集多项功能于一体，能提升眼科诊疗效率，丰富集团产品组合。 该产品自2024年起在美国上市，是一款 集生物测量仪、角膜地形图、前节OCT于一体 的多模影像诊断平 台，能够在屈光、角膜病、青光眼、视光等多个眼科亚专科领域发挥重要作用。在屈光手术中， ANTERION眼科检测仪能精准评估角膜上皮厚度和视觉质量，引导个性化切削 方案；在白内障手术中，结 合角膜地形图与生物测量数据，可降低术后屈光意外风险。 ANTERION 眼科检测仪运用 1300nm 波长的 SS-OCT 技术 ，具有穿透力强、扫描速度快、成像分辨率高 的特点，结合 动眼追踪（Eye-tracking）和光线追踪（Ray-tracing）技术 ，提供高效全面的眼前节诊 疗解决方案，一台设备即可完 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 角膜共聚焦顯微鏡取得國家醫療器械註冊證 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 本公告由高視醫療科技有限公司（「本公司」，連同其附公司統稱「本集團」）自 願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於近日，本公司全資附屬公司高 視創新科技有限公司（「高視創新」）自主研發的型號為T3-600及T3-400的角膜共 聚焦顯微鏡取得由江蘇省藥品監督管理局批准的醫療器械註冊證。 該角膜共聚焦顯微鏡通過技術創新實現行業突破，成為國內同類設備中首款 兼具寬視場與高分辨率。該設備採用激光光源和斷層共焦掃瞄技術，將掃瞄視 場提升至600×600μm，光學分 ...